Outstanding is just 13.6 ML, so what are they going to get by doing RS 1:20 now? Why would they be doing 1:20 RS other than just for screwing stockholders?
If they issue more stock, if that newly issued stock not going to come into float, then where’s it going to go? Is that newly issued stock going to come to market for sell immediately?
R/S not effective yet - FINRA has to declare the effective date.
And the ticker will likely change to GTHPD
The S-1 and S-1/A are both preliminary.
Looks like the R/S will happen first, then the offering.
And still no word about when the clinical trials will start in the USA. The clinicaltrials.gov page still shows the Primary Completion Date as Sept. 30, 2022, but that likely will get pushed back.
Market Data 
Markets 
AI
